{"id":842963,"date":"2025-04-28T17:11:15","date_gmt":"2025-04-28T21:11:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/"},"modified":"2025-04-28T17:11:15","modified_gmt":"2025-04-28T21:11:15","slug":"editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/","title":{"rendered":"Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., April  28, 2025  (GLOBE NEWSWIRE) &#8212; Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that five abstracts have been accepted for presentation, including one oral presentation, at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 13 \u2013 17, 2025, in New Orleans, LA, and virtually. The Company is presenting preclinical data to support its development of transformative <em>in vivo <\/em>gene editing medicines.<\/p>\n<p>Editas Medicine presentations at ASGCT include:<\/p>\n<ul type=\"disc\">\n<li>Oral presentation of<em> in vivo <\/em>preclinical data from humanized mouse and non-human primate (NHP) studies using targeted lipid nanoparticles (tLNPs) to deliver <em>HBG1\/2<\/em> promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) and\/or hematopoietic stem cells (HSCs) in bone marrow.<\/li>\n<li>Preclinical proof of concept for an undisclosed liver target using <em>in vivo<\/em> CRISPR editing to upregulate target protein expression and reduce a disease-associated biomarker in a relevant mouse disease model.<\/li>\n<li>Proof of concept results from the first <em>in vivo<\/em> mouse and NHP studies demonstrating high levels of target gene editing in the liver and corresponding biomarker response following intravenous administration of AsCas12a messenger RNA (mRNA) and chemically modified guide RNAs (gRNAs) delivered using LNPs from Genevant.<\/li>\n<li>Additional preclinical data demonstrating <em>in vivo<\/em> gene editing capabilities towards developing transformative <em>in vivo <\/em>medicines, including guide modification and targeting moiety optimizations to increase potency and improve gene editing outcomes <em>in vivo<\/em>.<\/li>\n<\/ul>\n<p>\u201cEditas Medicine is making significant progress towards the clinic with our <em>in vivo <\/em>medicines in preclinical development for people living with serious diseases,\u201d said Linda C. Burkly, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine. \u201cWe look forward to sharing further proof of concept data at ASGCT, including preclinical data confirming our ability to increase the level of a protein to address diseases caused by loss of function or deleterious mutations via our differentiated gene upregulation editing strategy. Our progress with tLNP delivery highlights the potential to execute our gene upregulation strategy across multiple tissues with our \u2018plug \u2018n play\u2019 approach.\u201d<\/p>\n<p>The complete list of Editas Medicine presentations is below. Abstracts can be accessed on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WNRXbdOAU0RzIkJwUtE2ZXA5HG60ihoDK7yEWN5qWneHl0tP94pFxIT5mkmFNUn6l62GdxgeX6gQdH4nFBz2CeSKqkdO4S0Kw1WzSNxapEc=\" rel=\"nofollow\" target=\"_blank\">ASGCT website<\/a>, and the presentations will be posted on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=70eY9gjtoPf2P8gnss_xt_WeGIKMjc0sq0HrxiijUsvMM2QPnXTg5ZPzEz2CesklZHLCHW-7YWWEWbkIfxi8zINeyhBgw_CmZyHBjtbgUzQ1wPpEq-4pnjO6ssy4EswHV57MrJFqMgocLfFX0pyZYQ==\" rel=\"nofollow\" target=\"_blank\">Editas Medicine website<\/a> during the conference.<\/p>\n<p>\n        <strong><br \/>\n          <u>Oral Presentation:<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <strong>Title:<\/strong><br \/>\n        <em>In Vivo<\/em> Delivery of HBG1\/2 Promoter Editing Cargo to HSC of Humanized Mouse and Non-Human Primate with Lipid Nanoparticles<br \/><strong>Session Date and Time:\u00a0<\/strong>Wednesday, May 14, 2025, 1:30 p.m. \u2013 1:45 p.m. CT <br \/><strong>Session Title:<\/strong>\u00a0Translational Applications of Base and Prime Editors<br \/><strong>Room:<\/strong>\u00a0265-268<br \/><strong>Final Abstract Number:<\/strong> AMA353<\/p>\n<p>\n        <strong><br \/>\n          <u>Poster Presentations:<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <strong>Title: <\/strong>Design and Development of Improved LNP Targeting Ligands for <em>In Vivo<\/em> Hematopoietic Stem Cell Editing<br \/><strong>Session Date and Time: <\/strong>Tuesday, May 13, 2025, 6:00 p.m. \u2013 7:30 p.m. CT<br \/><strong>Session Title: <\/strong>Tuesday Poster Reception<br \/><strong>Presentation Room:<\/strong>\u00a0Poster Hall, Hall 12<br \/><strong>Final Abstract Number: <\/strong>AMA245<\/p>\n<p>\n        <strong>Title: <\/strong>Design of Chemically Modified AsCas12a Guide RNAs for Increased Potency of LNP-Delivered Gene Editing Cargos<br \/><strong>Session Date and Time: <\/strong>Tuesday, May 13, 2025, 6:00 p.m. \u2013 7:30 p.m. CT<br \/><strong>Session Title: <\/strong>Tuesday Poster Reception<br \/><strong>Presentation Room:<\/strong>\u00a0Poster Hall, Hall 12<br \/><strong>Final Abstract Number:<\/strong>\u00a0AMA420<\/p>\n<p>\n        <strong>Title: <\/strong><br \/>\n        <em>In Vivo<\/em> Gene Editing and Disease-Associated Biomarker Reduction for Multiple Liver Targets in Non-human Primate Using AsCas12a Nuclease Delivered by LNP<br \/><strong>Session Date and Time: <\/strong>Wednesday, May 14, 2025, 5:30 p.m. \u2013 7:00 p.m. CT<br \/><strong>Session Title: <\/strong>Wednesday Poster Reception<br \/><strong>Presentation Room:<\/strong>\u00a0Poster Hall, Hall 12 <br \/><strong>Final Abstract Number:<\/strong>\u00a0AMA640<\/p>\n<p>\n        <strong>Title: <\/strong><br \/>\n        <em>In Vivo<\/em> CRISPR Editing of Genetic Regulatory Regions Results in Functional Upregulation of Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice<br \/><strong>Session Date and Time: <\/strong>Wednesday, May 14, 2025, 5:30 p.m. \u2013 7:00 p.m. CT<br \/><strong>Session Title:<\/strong> Wednesday Poster Reception<br \/><strong>Presentation Room:<\/strong>\u00a0Poster Hall, Hall 12 <br \/><strong>Final Abstract Number:<\/strong>\u00a0AMA351<\/p>\n<p>\n        <strong>About<\/strong>\u00a0<strong>Editas Medicine<\/strong><br \/>As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR\/Cas12a and CRISPR\/Cas9 genome editing systems into a robust pipeline of <em>in vivo <\/em>medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision <em>in vivo <\/em>gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute\u2019s Cas12a patent estate and Broad Institute and Harvard University\u2019s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bgpWDUbV-XxVsOOIf5XMY932pKnOjIOpG5OYm6rqLtBi5iEtYe_dBz4Mra_ieixtMGlKdo-eWYF6WcoRGPiBZvuSBJU2KzTWByj7WHphDLk=\" rel=\"nofollow\" target=\"_blank\">www.editasmedicine.com<\/a>.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0MDI5MCM2OTA4OTE0IzIwMjYwMjc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MWRhZmFmYjAtMWY3NS00NzUxLTkyYzMtODA3NWRmYjU2ODNkLTEwMzc1OTktMjAyNS0wNC0yOC1lbg==\/tiny\/Editas-Medicine-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Media and Investor Contact:\r\nir@editasmed.com \u00a0<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) &#8212; Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that five abstracts have been accepted for presentation, including one oral presentation, at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 13 \u2013 17, 2025, in New Orleans, LA, and virtually. The Company is presenting preclinical data to support its development of transformative in vivo gene editing medicines. Editas Medicine presentations at ASGCT include: Oral presentation of in vivo preclinical data from humanized mouse and non-human primate (NHP) studies using targeted lipid nanoparticles (tLNPs) to deliver HBG1\/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) and\/or hematopoietic stem cells &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-842963","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) &#8212; Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that five abstracts have been accepted for presentation, including one oral presentation, at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 13 \u2013 17, 2025, in New Orleans, LA, and virtually. The Company is presenting preclinical data to support its development of transformative in vivo gene editing medicines. Editas Medicine presentations at ASGCT include: Oral presentation of in vivo preclinical data from humanized mouse and non-human primate (NHP) studies using targeted lipid nanoparticles (tLNPs) to deliver HBG1\/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) and\/or hematopoietic stem cells &hellip; Continue reading &quot;Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-28T21:11:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0MDI5MCM2OTA4OTE0IzIwMjYwMjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting\",\"datePublished\":\"2025-04-28T21:11:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\\\/\"},\"wordCount\":731,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0MDI5MCM2OTA4OTE0IzIwMjYwMjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\\\/\",\"name\":\"Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0MDI5MCM2OTA4OTE0IzIwMjYwMjc=\",\"datePublished\":\"2025-04-28T21:11:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0MDI5MCM2OTA4OTE0IzIwMjYwMjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0MDI5MCM2OTA4OTE0IzIwMjYwMjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting - Market Newsdesk","og_description":"CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) &#8212; Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that five abstracts have been accepted for presentation, including one oral presentation, at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 13 \u2013 17, 2025, in New Orleans, LA, and virtually. The Company is presenting preclinical data to support its development of transformative in vivo gene editing medicines. Editas Medicine presentations at ASGCT include: Oral presentation of in vivo preclinical data from humanized mouse and non-human primate (NHP) studies using targeted lipid nanoparticles (tLNPs) to deliver HBG1\/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) and\/or hematopoietic stem cells &hellip; Continue reading \"Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-28T21:11:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0MDI5MCM2OTA4OTE0IzIwMjYwMjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting","datePublished":"2025-04-28T21:11:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/"},"wordCount":731,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0MDI5MCM2OTA4OTE0IzIwMjYwMjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/","name":"Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0MDI5MCM2OTA4OTE0IzIwMjYwMjc=","datePublished":"2025-04-28T21:11:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0MDI5MCM2OTA4OTE0IzIwMjYwMjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0MDI5MCM2OTA4OTE0IzIwMjYwMjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-preclinical-data-demonstrating-progress-in-the-development-of-an-in-vivo-gene-editing-pipeline-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/842963","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=842963"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/842963\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=842963"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=842963"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=842963"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}